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modulate multiple cellular processes independently of ER status. Here, we describe the ER-independent
effects of tamoxifen on tumor metabolism. Using combined pharmacological and genetic knockout
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complex I, resulting in an increase in the AMP/ATP ratio and activation of the AMPK signaling pathway in
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pathway and translation. Tamoxifen treatment also reprograms cellular metabolism by promoting
glycolysis, and altering fatty acid metabolism, leading to the depletion of intracellular lipid stores. By
using agents which target concurrently distinct adaptive responses to tamoxifen-mediated metabolic
reprogramming, we demonstrate increased cytotoxicity. Tamoxifen synergizes with glycolytic inhibitors to
kill breast cancer cells and can preferentially kill oxidative phosphorylation-dependent populations. Our
results demonstrate novel metabolic perturbations by tamoxifen in tumor cells which can be exploited to
expand the therapeutic potential of tamoxifen treatment beyond ER+ breast cancer.
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ABSTRACT
TAMOXIFEN MEDIATED METABOLIC STRESS: MOLECULAR MECHANISM AND
THERAPEUTIC OPPERTUNITIES

Natalie A. Daurio
Constantinos Koumenis
Tamoxifen is the most widely used adjuvant chemotherapeutic for the treatment of
estrogen receptor (ER) positive breast cancer, yet a large body of clinical and preclinical
data indicates that tamoxifen can modulate multiple cellular processes independently of
ER status. Here, we describe the ER-independent effects of tamoxifen on tumor
metabolism. Using combined pharmacological and genetic knockout approaches, we
demonstrate that tamoxifen inhibits oxygen consumption via inhibition of mitochondrial
complex I, resulting in an increase in the AMP/ATP ratio and activation of the AMPK
signaling pathway in vitro and in vivo. We also show that tamoxifen-induced cytotoxicity
is modulated by isoform-specific effects of AMPK signaling, in which AMPKα1 promotes
cell death through inhibition of the mTOR pathway and translation. Tamoxifen treatment
also reprograms cellular metabolism by promoting glycolysis, and altering fatty acid
metabolism, leading to the depletion of intracellular lipid stores. By using agents which
target concurrently distinct adaptive responses to tamoxifen-mediated metabolic
reprogramming, we demonstrate increased cytotoxicity. Tamoxifen synergizes with
glycolytic inhibitors to kill breast cancer cells and can preferentially kill oxidative
phosphorylation-dependent populations. Our results demonstrate novel metabolic
perturbations by tamoxifen in tumor cells which can be exploited to expand the
therapeutic potential of tamoxifen treatment beyond ER+ breast cancer.
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CHAPTER 1: GENERAL INTRODUCTION

1

Breast cancer (BC) is responsible for 1.1 million cancer diagnoses annually world
wide and 410,000 deaths1. It is second leading cause of cancer related deaths in women
in the United States. Breast cancer deaths are not the result of the primary tumor but of
recurrent and metastatic disease. Approximately 10-15% of patients will develop
metastatic disease in the first 3 years following diagnosis however, the development of
metastatic lesions after 10 years or more following treatment of the primary tumor is not
unusual2. Therefore breast cancer patients remain at risk for metastatic disease for their
entire life.
Breast cancer is a highly heterogeneous disease with distinct histopathological
and molecular features that impact disease treatment and prognosis. As a result, a
classification system with distinct BC subtypes is used to guide clinical decision making
in combination with traditional variables such as tumor size, invasiveness, and node
involvement. While scientific reports propose multiple different classification schemes,
BC can be divided into three categories: luminal BC, which usually express estrogen
receptor (ER) and/or progesterone receptor (PR), human epidermal growth factor
receptor 2 (HER2) overexpressing BC, and basal BC. Basal BC is also known as triple
negative BC referencing the lack of significant ER, PR, or HER2 expression and is the
most heterogeneous subtype. Triple negative BC is also the most aggressive disease
and is without any standard targeted therapy options.3
Tamoxifen is the most widely used non-steroidal selective estrogen receptor
modulator (SERM) for adjuvant therapy of estrogen receptor-positive (ER+) breast
cancer (BC). SERMs are unique in that they exert ER agonist or antagonist properties in
a tissue specific manner. Originally designed as a contraceptive, then used as a fertility
agent, tamoxifen has been in the clinic since 1966. Patients on standard treatment
receive tamoxifen at 20 mg/day for 5 years with initiation during, or shortly after, surgical
2

removal of the primary tumor and treatment with ionizing radiation or cytotoxic
chemotherapy. Tamoxifen therapy has reduced disease recurrence by half and overall
mortality by one-third in ER+ BC patients4. As an anti-cancer agent tamoxifen has a
relatively safe toxicity profile with the most common side effects including hot flashes
and irregular menses. Due to its SERM effects, Tamoxifen treatment is also linked to an
increased risk for endometrial cancer and rare thromboembolic events. However other
positive effects have been reported such as an increase in bone mineral density in postmenopausal women as well as a decrease in total cholesterol and LDL levels that may
contribute to a decrease in cardiovascular events that are seen in treated populations4.
The development of tamoxifen resistance remains a significant clinical problem.
Approximately one-third of women treated with tamoxifen will develop recurrent disease.
Tamoxifen resistant tumors can be treated with second-generation anti-estrogenic
therapies but total endocrine resistance often emerges. Only about 15% of these
tamoxifen-resistant cases will lose ER expression. Additional mechanisms for the
emergence of resistance are not well understood but have been reported to include
changes in receptor post-translational modifications, altered downstream signal
transduction, cross-talk with other growth receptors, and changes in expression of coactivators and other transcription factors5.
The anti-tumor effects of tamoxifen are attributed primarily to its antiproliferative
activity via competitive inhibition of the ER in breast tissue6. Several studies have
previously described non-ER dependent effects of tamoxifen such as the inhibition of
protein kinase C (PKC)7–9 and the sensitization of ER-negative tumors to
chemotherapeutic agents10–12. Furthermore, during the past two decades, over 25
clinical trials have been published reporting the effects of “high dose” tamoxifen (i.e.
doses above those needed to inhibit tumor cell ER activity) ranging from 80 to 720
3

mg/day12 to treat non-breast cancers including glioma13–16, melanoma17,18 and others19,20,
as a single agent or in combination with chemotherapeutics. While these Phase I and II
trials showed variable clinical benefit, they clearly demonstrated the safety of high dose
tamoxifen in diverse patient populations. Pharmacodynamic analyses indicated that
tamoxifen could reach plasma concentrations as high as 8 µM19 and additional
preclinical studies indicated that tamoxifen accumulates in tumor tissue at 60-70 times
the plasma concentration21. Therefore, further studies on “high dose” tamoxifen are
clinically relevant and may result in expanded indications for this affordable and welltolerated chemotherapeutic.
The chemical properties of tamoxifen as a lipophilic weak base contribute to its
high partition into lipid bilayers and tamoxifen has been previously described to have
inhibitory effects on mitochondrial respiratory rate22 and membrane potential23. Agents
targeting metabolic processes are of particular interest for cancer therapies due to the
unique metabolic phenotype exhibited by tumors. As rapidly proliferating masses of
cells, tumors require large pools of macromolecules to generate the proteins, lipids, and
nucleotide content necessary to divide as well as sufficient quantities of ATP and
reducing equivalents to power these processes24. In 1926, Otto Warburg first described
the preference of cancer cells for converting glucose to lactate via glycolysis, even under
sufficient oxygenation, an effect that is known as The Warburg Effect, or “aerobic
glycolysis”25. He hypothesized that this occurs due to defects in cancer mitochondria,
leaving cancer cells dependent on glycolysis for ATP production. However, more recent
research has shown that cancer mitochondria are quite functional and has suggested
that this elevation in glycolysis results from the need for precursor molecules from
glycolytic intermediates for synthesis of fatty acids, nucleotides and amino acids.
Tricarboxylic acid (TCA) cycle intermediates can also be used as carbon sources for
4

biosynthetic pathways26. Elevated glutamine uptake seen in cancer also contributes
carbons to these synthetic pathways necessary for rapid cell division24.
Metabolic processes are highly regulated and to achieve the phenotype
necessary for rapid proliferation tumor promotion by certain oncogenes alter the
metabolic characteristics of cells as a requirement for transformation 27. Oncogenes
including myc, nuclear factor-κB (NF- κB), AKT, various tyrosine kinase growth factor
receptors, Ras, phosphatidylinositol 3-kinases (PI3Ks) and mammalian target of
rapamycin (mTOR) pathways, and hypoxia- induced factors (HIFs) all enhance
transcription of factors that promote glycolysis and glutaminolysis. Myc activation also
promotes an increased rate of protein synthesis. Additionally, changes in metabolic
enzymes themselves also play a role in tumor promotion including mutations in isocitrate
dehydrogenase 1 (IDH1), succinate dehydrogenase and fumarase28. Tumor suppressors
such as p53 and PTEN also play a role in metabolic transformation. Mutations or loss of
expression of these genes have been shown to promote the aerobic glycolysis
phenotype29.
The cancer metabolic phenotype is essential for the survival and growth of
tumors, making these pathways appealing therapeutic targets. Antimetabolites were the
first successful cancer therapies to halt tumor growth by interfering with the ability to
synthesize required molecules. DNA replication was targeted with small molecules
analogs of essential purine and pyrimidine metabolites including methotrexate, 5fluoruracil, and gemcitabine30. Many therapeutic strategies have also been employed to
target the dependence of cancer on glycolysis, including use of glucose analogs such as
2-deoxy-glucose (2-DG) and inhibition of glycolysis enzymes including hexokinase II
(HK2), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and phosphofructokinase
(PFK), as well as blocking the export of lactate, and use of carbohydrate restricted
5

diets31. Amino acid metabolism has been another focus of drug development efforts.
Inhibition of glutamine uptake and metabolism has shown some preclinical promise and
L-aspariginase has been used clinically as a successful treatment for leukemia.
Significant effort has also been directed towards developing inhibitors of fatty acid
synthesis enzymes including fatty acid synthase (FASN), ATP citrate lyase (ACLY), and
acetyl-CoA carboxylase (ACC). The success of these therapies targeting metabolic
pathways have been limited by normal tissue toxicity as well as by metabolic plasticity or
metabolic pathway redundancy that allows cells to overcome a blockade by upregulation
of compensatory pathways27,32. As a result, combination therapies targeting multiple
arms of metabolic pathways or the combination of a metabolic therapy with a cytotoxic
chemotherapeutic are likely to be more successful.
Targeting of oncogenes that promote the cancer metabolic phenotype is another
area of drug discovery research that has gained momentum in recent years. The term
“oncogene addiction” describes tumor dependence on specific oncogene signaling
pathways for continued tumor maintenance and progression. In these cases, deprivation
of oncogene signaling results in tumor regression, therefore, these genes are the focus
of targeted therapeutic development. Many of these oncogenes contribute to the cancer
metabolic phenotype and pathway blockade often results in significant metabolic
alterations. Targeting of mutant BRAF in melanoma and KRAS in pancreatic cancer,
results in a reversal of the Warburg effect. Inhibition of PI3K, AKT, and mTOR has long
been of interest due to their role in cell proliferation. Blockade of these pathways have
been reported to result in both inhibition of glycolysis as well as oxidative
phosphorylation33,34. The combination of these oncogene-targeted therapies with
inhibitors of compensatory metabolic pathways may also increase efficacy and prevent
resistance.
6

While upregulation of glycolytic and biosynthetic metabolic pathways plays an
essential role in tumor progression, the function of mitochondrial respiration in cancer
biology should not be discounted. Oxidative phosphorylation has been reported to
provide 25-60% of the ATP pools for cancer cells and substrate availability has been
shown to regulate oxidative capacity. Therefore, at times of glucose deprivation,
mitochondria respiration may increase to maintain cellular function and the use of
glutamine as a carbon source requires mitochondrial oxidative capacity35. Electron
transport also functions to regenerate nicotinamide adenine dinucleotide (NAD+) and
flavin adenine dinucleotide (FAD)35. Moreover, TCA cycle intermediates are required for
synthesis of amino acids and nucleotides from both glucose and glutamine. Oxidative
phosphorylation (OXPHOS) regeneration of reducing equivalents is necessary for
continued TCA cycle activity36. Cancer heterogeneity also highlights the importance of
mitochondrial metabolism in cancer. Cancer stem cells and tumor initiating cells have
been showed to have higher levels of OXPHOS37,38. Respiration has also been shown to
support the extravasation and intravasation processes required for metastasis39.
Moreover, aggressive and drug resistant populations also characteristically have
increased levels of OXPHOS38,40. Dormant cancer cells also may also depend on
respiration to survive nutrient depleted conditions, allowing for cancer recurrence37,41.
Since mitochondrial oxidative phosphorylation plays a significant role in cancer
promotion, pharmacological inhibition of respiration may be an important drug target for
the advancement of therapeutic options. Evidence from current literature supports the
efficacy of this strategy. Metformin targeting of complex I of the electron transport chain
has been shown to reduce tumorigenesis42. Resistance to targeted therapies in BRAF
and KRAS driven tumors limits the therapeutic options in cancers such as melanoma
and pancreatic cancer. The drug resistant populations are thus dependent on elevated
7

OXPHOS and drugs that target mitochondrial metabolism, such as biguanides, have
potential utility in targeting such resistant populations by synthetic-lethality approaches
38,40,43–45

. Moreover, tumor hypoxia is a significant obstacle to the clinical success of

ionizing radiation and other DNA damaging agents. Inhibition of mitochondrial respiration
has been validated as a strategy to reduce tumor hypoxia and sensitize tumors to these
therapies46.
One of the consequences of OXPHOS inhibition, especially in metabolically
active cancer cells, is the activation of the AMP-activated protein kinase (AMPK), the
major regulator of cellular energy homeostasis. AMPK is activated when the AMP:ATP
ratio increases, signaling a loss in cellular energy charge. Once activated, AMPK
restores cellular energy levels by promoting catabolic and inhibiting anabolic
processes47. AMPK is universally expressed across all eukaryotes as a heterotrimeric
protein composed of an alpha catalytic subunit, and beta and gamma regulatory
subunits. The gamma subunit contains four surface adenyl binding sites containing
tandem repeats known as CBS repeats. Mammalian AMPK has a constitutively bound
AMP at site 4 while site 2 remains unoccupied. AMP and ATP compete for binding at
sites 1 and 348–50. Interestingly, expression of adenylate kinase maintains the reaction
2ADP↔AMP+ATP at equilibrium. Therefore any loss in cellular energy levels will result
in an increase in both AMP and ADP. However, since intracellular AMP pools are much
smaller than ADP pools, their relative increase will be more significant making it logical
that AMPK is most sensitive to the AMP/ATP ratio. When AMP binds these sites, a
conformational change is induced that prevents the dephosphorylation of the catalytic
alpha subunit of AMPK by phosphatases and enhances phosphorylation by upstream
kinases. More specifically, binding at site 1 results in allosteric activation of AMPK and
binding at site 3 promotes phosphorylation. The alpha subunit is phosphorylated on
8

Thr172 in the activation loop increasing kinase activity of the Ser/Thr kinase domain at
the amino terminus50.
The best described AMPK-kinase is liver kinase B1 (LKB1). LKB1 is a known
tumor suppressor and is mutated in the inheritable Peutz-Jeghers syndrome
characterized by benign intestinal polyps and mucocutaneous pigmentation with an
increased risk for developing tumors of multiple lineages. LKB1 functions in a complex
with ste20-related adaptor (STRAD) and mouse protein 25 (MO25). Activation of AMPK
by metabolic stress has been shown to be diminished in LKB1-null cells51. AMPK can
also be activated by calcium-calmodulin kinase kinase 2 (CaMKK2), linking changes in
intracellular [Ca2+] to activation of AMPK. Many other kinases have been reported to
phosphorylate AMPK including transforming growth factor β-activated kinase (TAK1) and
sestrins47.
Once activated, AMPK signals downstream to restore cellular energy charge.
AMPK promotes glycolysis through increased glucose transporter (GLUT) 1 and 4
expression increasing glucose uptake as well as activation of 6-phosphofructo-2kinase/fructose-2,6-biphosphatase (PFKFB). AMPK also reduces protein synthesis
through phosphorylation of tuberous sclerosis complex 2 (TSC2) and raptor resulting in
inhibition of the mTOR pathway. Activation of AMPK promotes autophagy through direct
phosphorylation of unc-51 like autophagy activating kinase 1 (ULK1) as well as through
inhibition of mTOR. Moreover, AMPK inhibits fatty acid synthesis by inhibiting ACC, the
enzyme responsible for converting acetyl-coA to malonyl-CoA the initial and rate limiting
step of fatty acid synthesis. In addition, AMPK promotes beta oxidation of fatty acids by
promoting the transcription of lipogenic enzymes via sterol regulatory element-binding
transcription factor 1 (SREBP1) 48,50.

9

Figure I-1: AMP-Activated Protein Kinase (AMPK) Pathway: AMPK is a heterotrimeric
protein that is activated by an increase in the AMP/ATP Ratio. Binding of AMP at the γ
subunit promotes phosphorylation of the α catalytic subunit by upstream kinases including
LKB1 and CamKK2. Once activated AMPK feeds downstream to turn off ATP consuming
processes and activate ATP generating processes.

The role of AMPK in cancer is quite complex as it has been reported to function
contextually as both a tumor suppressor or tumor promoter 49. AMPK can function as a
tumor promoter by helping cancer cells to survive and adapt to metabolic stress that is
characteristic of tumor microenvironments and oncogene activation. AMPK activation
can allow cells to switch between fuel sources including glucose, glutamine and fatty
acids, in order to tolerate nutrient deprivation and may activate a cell cycle arrest to
allow tumor cells to survive particularly lean conditions. AMPK also plays a pro-survival
role through activation of autophagy49.The role of AMPK as a mediator of the tumor
suppressor properties of LKB1 has also been the focus of much research. Whole body
knock out of AMPKα1 resulted in an increase in c-myc lymphoma development52 and
expression of a dominant negative AMPK promoted prostate cancer cell proliferation53.
Moreover, patients on metformin, an AMPK activator used in diabetes treatment, have
10

been reported to have a lower incidence of cancers than metformin-naive diabetics48.
Some of the tumor suppressor effects of AMPK have been attributed to its role in
suppression of macromolecular synthesis pathways and its suppression of the Warburg
effect. While acute AMPK activation promotes glycolysis, long term activation shifts cells
towards a more oxidative phenotype by promoting mitochondrial biogenesis and
transcription of oxidative enzymes. Moreover, inhibition of the mTOR pathway decreases
translation of Hif-1α, a transcription factor that drives the Warburg effect51,52. Additional
tumor suppressor functions of AMPK include the activation of cell cycle arrest through
the stabilization of p53, p21 and p2751. Due to the decreased cancer incidence in
metformin treated patients, considerable research has been directed towards developing
metformin and other AMPK activators as cancer therapeutics.
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Hypothesis:

Based on published studies mentioned above and our preliminary results with
tamoxifen and OXPHOS, we formulated the central hypothesis that tamoxifen inhibits
oxygen consumption through an ER-independent direct effect on the mitochondria that
results in significant alterations in metabolism and cell signaling that can be exploited for
therapeutic benefit. To test this hypothesis, we first investigated the mechanism by
which tamoxifen inhibits oxygen consumption. This work demonstrated that tamoxifen
inhibits oxygen consumption by acting directly on the mitochondria, upstream of complex
II and independently of ER signaling. We then characterized the consequences of
tamoxifen inhibition of OXPHOS on cell signaling and metabolism. We have shown that
tamoxifen treatment results in a rapid and robust activation of the AMPK pathway in vitro
and in vivo, and downstream effects are mediated in an isoform specific manner.
Tamoxifen treatment also results in an increase in glycolysis and alterations in fatty acid
metabolism. We then determined if the metabolic effects of tamoxifen can be used for
therapeutic benefit. This work demonstrates that combination of tamoxifen and glycolytic
inhibitors synergize to cause increased cytotoxicity and that tamoxifen inhibition of
OXPHOS can be used to target OXPHOS addicted cancer populations. Overall, this
work describes a novel mechanism of action for an extensively used drug and identifies
new therapeutic opportunities.
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CHAPTER 2: TAMOXIFEN INHIBITS MITOCHONDRIAL COMPLEX I AND
ACTIVATES THE AMPK PATHWAY.

Sections of this chapter contribute to the published manuscript:

Natalie A. Daurio, Stephen W. Tuttle, Andrew J. Worth, Ethan Y. Song, Julianne M.
Davis, Nathaniel W. Snyder, Ian A. Blair, and Constantinos Koumenis. AMPK
activation and metabolic reprogramming by tamoxifen through estrogen receptorindependent mechanisms suggests new uses for this therapeutic modality in
cancer treatment. Cancer Res OnlineFirst March 28, 2016.
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Introduction:
The anti-tumor effects of tamoxifen in BC are attributed primarily to its
antiproliferative activity via competitive inhibition of the ER in breast tissue 6. Several
studies have previously described non-ER dependent effects of tamoxifen such as the
inhibition of Protein Kinase C (PKC)9 and the sensitization of ER-negative tumors to
chemotherapeutic agents10. Furthermore, during the past two decades, over 25 clinical
trials have been published reporting the effects of “high dose” tamoxifen (i.e. doses
above those needed to inhibit ER activity) ranging from 80 to 720 mg/day 12 to treat nonbreast cancers including glioma16, melanoma17 and others19,20, as a single agent or in
combination with chemotherapeutics. While these Phase I and II trials showed variable
clinical benefit, they clearly demonstrated the safety of high dose tamoxifen in diverse
patient populations. Pharmacodynamic analyses indicated that tamoxifen could reach
plasma concentrations as high as 8 µM19 and additional preclinical studies indicated that
tamoxifen accumulates in tumor tissue at 60-70 times the plasma concentration21.
Therefore, further studies on “high dose” tamoxifen are clinically relevant and may result
in expanded indications for this affordable and well-tolerated chemotherapeutic.
The chemical properties of tamoxifen as a lipophilic weak base contribute to its
high partition into lipid bilayers and tamoxifen has been previously described to have
inhibitory effects on mitochondrial respiratory rate22 and membrane potential23. Cells in
which oxidative phosphorylation (OXPHOS) is inhibited by pharmacologically targeting
members of the mitochondrial respiratory chain, or due to lack of oxygen (hypoxia),
exhibit a compensatory increase in glycolysis. For example, metformin, a diabetes drug
showing promise as a cancer therapeutic, was recently demonstrated to inhibit
Mitochondrial complex I and to upregulate glycolysis 42.
14

One of the consequences of OXPHOS inhibition, especially in metabolically
active cancer cells, is the activation of the AMP-activated protein kinase (AMPK), the
major regulator of cellular energy homeostasis. AMPK is activated when the AMP:ATP
ratio increases, signaling a loss in cellular energy charge. AMP binds to the gamma
subunit of AMPK inducing a conformational change that prevents the dephosphorylation
of the catalytic alpha subunit of AMPK by phosphatases. This enhances phosphorylation
of AMPK by upstream kinases including LKB1 and CaMKK2. Once activated, AMPK
restores cellular energy levels by promoting catabolic and inhibiting anabolic
processes47. The role of AMPK in cancer is quite complex as it has been reported to
function contextually as both a tumor suppressor or promoter49.
Based on these studies, we investigated whether tamoxifen had an impact on
cellular metabolism and metabolic signaling. Here we report the ability of tamoxifen to
inhibit oxygen consumption, through a direct effect on mitochondria, upstream of
complex II. We also observe rapid (<10 min) and acute activation of AMPK in vitro and in
vivo in an ER-independent manner. Moreover, we demonstrate that activation of the
AMPK pathway by tamoxifen promotes cell death in triple-negative breast cancer cells in
an AMPK-isoform specific manner.

Results:
While tamoxifen has been reported to affect mitochondrial electron transport and
membrane potential, its effects on oxygen consumption have not been adequately
described. A Clark electrode was used to measure oxygen consumption of cells.
Tamoxifen, at low M doses, inhibited oxygen consumption in a dose dependent manner
in both ER+ MCF7 cells and triple-negative MDA-MB-231 cells (Figure II-1A). Tamoxifen
15

also inhibited oxygen consumption in a panel of 6 non-breast cancer cell lines including
prostate, glioma, lung and cervical cancer cell lines (Figure II-1B). The active metabolite
of tamoxifen, 4-hydroxy-tamoxifen (4OH-Tam) also inhibited oxygen consumption while
the ER antagonist fulvestrant, which inhibits ER activity by blocking ER dimerization and
promoting degradation of the ER 54, did not have a significant effect on oxygen
consumption. Interestingly, supra-physiologic doses of estradiol, the endogenous ligand
of the ER, also inhibited BC cell oxygen consumption (Figure II-1C). This suggests that
inhibition of ER signaling is not responsible for the rapid inhibition of oxygen
consumption in response to tamoxifen treatment. To further rule out involvement of ER
signaling in tamoxifen-mediated inhibition of oxygen consumption, we used both
pharmacological and genetic means to knock down ER expression. Treatment of MCF7
cells with fulvestrant reduced ER expression (Figure II-1D insert). Subsequent treatment
with tamoxifen recapitulated the dose dependent effects on oxygen consumption seen
with the control treated MCF7 cells (Figure II-1D). We then used the CRISPR-Cas9
system to knock out ERα from LCC1 cells, a variant of the MCF7 line which expresses
functional ER but is not dependent on its signaling for proliferation (Figure II-1E)55. The
ability of tamoxifen to inhibit oxygen consumption in the LCC1-crspER cells was no
different from the parental LCC1 cells (Figure II-1F) further supporting the notion that
tamoxifen inhibits oxygen consumption independently of ER signaling.
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Figure II-1: Tamoxifen Inhibits cellular oxygen consumption in an ER independent
manner. A. Cellular oxygen consumption measurements in response to increasing doses of
tamoxifen in ER+ MCF7 cells and ER- MDA-MB-231 cells. B. Fraction of oxygen
consumption rate remaining after tamoxifen treatment at 30μM in a panel of cancer cell lines.
C. Oxygen consumption measurements of BC cells treated with increasing doses of
tamoxifen, 4OH-tamoxifen, fulvestrant, or β-estradiol. D. Oxygen consumption measurements
of MCF7 cells pretreated with fulvestrant or vehicle control plus increasing doses of
tamoxifen. Insert: Immunoblot of ER expression following fulvestrant treatment. E. Cellular
oxygen consumption measurements of LCC1 cells and LCC1 cells with CRISPR-Cas9
mediated deletion of ERα treated with increasing doses of tamoxifen. Data are the average of
three independent experiments ±SEM, *P<0.05 **P<0.01 ***P<0.001.
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To determine if the effect of tamoxifen on oxygen consumption was due to a
direct interaction with mitochondria, we isolated mitochondrial from mouse liver.
Tamoxifen inhibited oxygen consumption in the presence of complex I substrates
glutamate and malate but not in the presence of complex II substrate succinate (Figure
II-2A). To investigate if tamoxifen affected cancer mitochondria similarly to mitochondria
isolated from healthy cells, we used digitonin to permeabilize MCF7 and MDA-MB-231
cells. Tamoxifen inhibited oxygen consumption of mitochondria by 60% in both
permeabilized cell lines. As seen in liver mitochondria, respiration of cancer
mitochondria could be rescued by supplementation with electron transport chain
complex II substrate succinate but not with complex I substrates, glutamate and malate
(Figures II-2B and II-2C). These effects of tamoxifen on mitochondria respiration are
similar to what is seen with rotenone, a known complex I inhibitor. For experimental
control we also determined that antimycin A, a complex III inhibitor, shuts down oxygen
consumption in both permeabilized cell lines in the presence of succinate (Figures II-2B
and II-2C). This indicates that the tamoxifen-mediated inhibition of oxygen consumption
occurs through a direct effect on mitochondria, upstream of complex II. Interestingly,
while intact MCF7 cells exhibit higher oxygen consumption rate than MDA-MB-231cells,
this difference is lost once the cells are permeabilized. This may indicate that the higher
rate of OXPHOS in MCF7 cells is due to a mechanism upstream of mitochondrial
function. In addition, differing cell sensitivity to digitonin may play a role in the basal and
succinate powered oxygen consumption rate. The addition of methyl succinate, a cellpermeable analog of succinate, reduced the ability of tamoxifen to inhibit oxygen
consumption in intact BC cells (Figure II-2D) and significantly increased cell survival of
MCF7 cells treated with tamoxifen (Figure II-2E). These results suggest that inhibition of
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mitochondrial function upstream of complex II mediates the effects of tamoxifen on
oxygen consumption and downstream effects.
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Previous Page - Figure II-2: Tamoxifen inhibits oxygen consumption at mitochondrial
complex I: A. Oxygen consumption measurements of mitochondria isolated from mouse
liver treated with tamoxifen in the presences of complex I or complex II substrates. B. Effect
of tamoxifen on oxygen consumption of digitonin permeabilized MCF7 and C. MDA-MB-231
cells in the presence of complex I or complex II substrates compared to other mitochondrial
electron transport inhibitors rotenone and antimycin A. D. Oxygen consumption
measurements of MCF7 and MDA-MB-231 cells treated with Tamoxifen alone or in the
presence of methyl succinate. E. Survival of MCF7 cells (N=6) treated with tamoxifen alone
or in the presence of methyl succinate. Data are the average of three independent
experiments ±SEM *P<0.05 **P<0.01. ***P<0.001.

Upon inhibition of oxygen consumption, it is expected that ATP synthesis via
OXPHOS would be reduced resulting in accumulation of AMP. To determine if inhibition
of oxygen consumption by tamoxifen alters cellular energy charge we quantified
intracellular AMP and ATP pools following tamoxifen treatment. Tamoxifen increased the
AMP:ATP ratio in MDA-MB-231 cells and MCF7 cells (Figure II-3A), the major activating
mechanism of AMPK, as soon as 5 min after tamoxifen treatment and this ratio further
increased following one hour of treatment. This increase in the AMP:ATP ratio correlated
with a concomitant increase in tamoxifen- induced AMPK phosphorylation of the
downstream signaling target acetyl-CoA carboxylase (ACC) and dephosphorylation of
the mTOR targets 70 kDa ribosomal protein s6 kinase 1 (p70S6K), ribosomal protein s6
(pS6), and eukaryotic translation initiation factor 4E binding protein 1 (4EBP1), in both
MCF7 (Figure II-3B) and MDA-MB-231 cells (Figure II-3C). To investigate if ER signaling
is necessary for tamoxifen activation of the AMPK pathway, we used pharmacologic and
genetic methods to block ER signaling. Pretreatment with fulvestrant to promote
downregulation of the ER did not inhibit tamoxifen activation of AMPK (Figure II-3D).
Furthermore, activation of AMPK in LCC1-crspER was comparable to that in LCC1
parental cells (Figure II-3E), indicating that the effects of tamoxifen on AMPK signaling
were also ER-independent.
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Figure II-3: Tamoxifen rapidly and acutely activates AMPK independently of estrogen
receptor signaling. A. HPLC quantification of the AMP:ATP ratio in MDA-MB-231 (N=6) and
MCF7 (N=3) cells treated with 30 μM tamoxifen for 5 and 60 mins, ±SEM *P<0.05 **P<0.01.
B. Immunoblot of AMPK pathway activation following treatment with 30μM tamoxifen in
MCF7 and C. in MDA-MB-231 cells. D. Immunoblot analysis of ER expression and AMPK
activation in MCF7 cells treated with 10 μM fulvestrant or DMSO for 4 hrs preceding
treatment with 30 μM tamoxifen over time. E. Immunoblot of AMPK activation in LCC1 cells
and LCC1 cells with CRISPR-Cas9 deletion of ERα following tamoxifen treatment.
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Upon an increase in the AMP:ATP ratio in the cell, AMP binds the gamma
subunit of AMPK which results in a conformational change that stabilizes
phosphorylation of the alpha subunit. Multiple AMPKα kinases have been reported, we
focused on the two most well-known: LKB1 and CaMKK2 to investigate their role in
AMPK activation upon tamoxifen treatment in BC cells. We used siRNA to knock down
expression of LKB1 and CaMKK2 in both MCF7 and MDA-MB-231 cell lines. In MCF7
cells knock down of either LKB1 or CaMKK2 alone was not sufficient to prevent
activation of AMPK. Concurrent knock down of both kinases was required to prevent
AMPK phosphorylation (Figure II-4A). In MDA-MB-231 cells siRNA knock down of LKB1
alone did not prevent tamoxifen-mediated phosphorylation of AMPK, while knock down
of CaMKK2 was sufficient to inhibit phosphorylation of AMPK upon treatment with
tamoxifen (Figure II-4A). However, under CaMKK2 knock down, treatment with
tamoxifen still resulted in phosphorylation of the AMPK target ACC, indicating that AMPK
was still activated even without phosphorylation as detected by immunoblot. This is
consistent with reports noting that AMP binding is enough to activate AMPK kinase56.
Similar to MCF7 cells, In MDA-MB-231 cells, knockdown of both LKB1 and CaMKK2
prevented both AMPK phosphorylation and downstream signaling, as monitored by
phosphorylation of the AMPK target ACC (Figure II-4A).
During the course of these experiments, no antibody was available that
accurately detected CaMKK2 expression by immunoblot, therefore we could not confirm
successful knock down by siRNA. To confirm the effects of CaMKK2 knock down of
AMPK activation following tamoxifen treatment we used the CaMKK2 inhibitor STO609.
As expected, treatment with this drug had no effect on tamoxifen-mediated AMPK
phosphorylation in MCF7 cells but did prevent phosphorylation of AMPK following
tamoxifen treatment in MDA-MB-231 cells (Figure II-4B). Thapsigargin was used as a
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control for CaMKK2-mediated AMPK phosphorylation. As expected, treatment with
STO609 prevented AMPK phosphorylation following Thapsigargin treatment (Figure II4B). Overall, these results indicate that tamoxifen-mediated AMPK phosphorylation is
mediated by multiple upstream AMPK-kinases and the extent of their importance is cell
type specific.

Figure II-4: LKB1 and CaMKK2 can both phosphorylate AMPK in response to
tamoxifen. A. Immunoblot of AMPK pathway activation with tamoxifen after siRNA knock
down of LKB1 and CaMKK2 in MCF7 and MDA-MB-231 cells. B. Immunoblot of the effect of
CaMKK2 inhibitor STO609 on Tamoxifen activation of AMPK.

23

To further dissect the biological role of AMPK in the cellular response to
tamoxifen, we used the CRISPR-cas9 system to knock out AMPKα1 in MDA-MB-231
cells. We observed that loss of AMPKα1 resulted in a compensatory increase in
AMPKα2 expression (Figure II-5A) and induced an increased survival in response to
tamoxifen treatment (Figure II-5B). This effect was recapitulated in MCF7 cells where
AMPKα1 inhibition by shRNA resulted in reduced levels of cleaved PARP and increased
survival upon tamoxifen treatment compared to shNT-transfected cells (Figures II-5C
and II-5D). To evaluate the impact of complete inhibition of AMPK catalytic activity on
cellular response to tamoxifen, we used siRNA to knock down AMPKα2 in both wild type
MDA-MB-231 cells and in crspAMPKα1 cells. Loss of AMPKα2 in MDA-MB-231 cells
resulted in increased cell death upon tamoxifen treatment whereas knockdown of
AMPKα2 in the AMPKα1 CRISPR knockout cells resulted in further increase in
tamoxifen-induced cytotoxicity (Figure II-5B). Notably, while the dual AMPKα1/2
knockdown showed the highest levels of tamoxifen toxicity as determined by the
modified MTT assay, the levels of apoptosis markers cleaved poly-ADP ribose
polymerase (PARP) and cleaved caspase 3 were quite low. This could be due to more
rapid processing of these markers under these conditions as indicated by complete loss
of total PARP in these cells. Interestingly, knockdown of either isoform of AMPKα
resulted in loss of phospho-ACC upon tamoxifen treatment, while loss of AMPKα1 alone
ameliorated the inhibition of the mTOR pathway following tamoxifen treatment. Induction
of autophagy remained unchanged upon AMPKα1 inhibition; however, knockdown of
both isoforms substantially reduced autophagy levels as seen by a reduction in
microtubule-associated protein light chain 3 (LC3) processing (Figure II-5A)
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Figure II-5: AMPKα1 and AMPKα2 mediate divergent effects on downstream effectors
and cellular survival after tamoxifen treatment. A. Immunoblot of AMPK pathway
activation and apoptotic markers after tamoxifen treatment in MDA-MB-231 cells with
CRSPR-cas9 knock out of AMPKα1 or siRNA knock down of AMPKα2. B. Modified MTT
assay of survival of AMPK knock down cells treated with 30 μM tamoxifen for 4 hrs. C.
Clonogenic survival of the effect of AMPK knockdown by shRNA in MCF7 cells treated with
30 μM tamoxifen. D. Immunoblot of AMPK activation and apoptotic markers following
tamoxifen treatment of MCF7 cells transfected with shNT or shAMPKα1. Data are the
average of three independent experiments ±SEM *P<0.05 **P<0.01 ***P<0.001

25

To further investigate the role of AMPK isoforms in the autophagic response of
BC cells to tamoxifen treatment we pretreated cells with E64d and pepstatin A to prevent
LC3-II recycling and monitored autophagic flux by immunoblot. While we saw reduced
levels of LC3-II in both siAMPKα2 and crspAMPKα1 conditions, MDA-MB-231 cells
require both AMPKα1 and AMPKα2 to be knocked down in order to significantly reduce
autophagy induction with tamoxifen treatment (Figure II-6A). This data suggests that
AMPK activation promotes autophagy in response to tamoxifen treatment.
To determine if the AMPK isoform-specific effects on the mTOR pathway
impacted upon cellular translation, we pulse-labeled MDA-MB-231 cells and
crspAMPKα1 cells with [35S]-cysteine and methionine. Translation was inhibited in both
cell lines, albeit to a substantially lesser extent in the crspAMPKα1 cells upon tamoxifen
treatment (Figure II-6B and II-6C).
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Previous page- Figure II-6: AMPKα isoform specific effects on downstream pathway
mediators. A. Immunoblot of LC3-I and LC3-II flux with tamoxifen treatment as affected by
AMPK status. Values represent Pixel intensity of LC3-I (top) or LC3-II (bottom) normalized to
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untreated control. B. Autoradiograph of S incorporation into proteins following tamoxifen
treatment in MDA-MB-231 cells or MDA-MB-231 cells with CRISPR-cas9 knock out of
35
AMPKα1. C. Quantification of S signal. Data are the average of three independent
experiments ±SEM *P<0.05 **P<0.01 ***P<0.001.

To determine if tamoxifen activates the AMPK pathway in vivo, we injected 4175
cells, a variant of the MDA-MB-231 triple negative breast cancer cell line57 into the
mammary fat pad of athymic nude female mice. After 3 weeks of tumor growth, 100
mg/kg tamoxifen was administered once daily for 3 days. Mean tamoxifen and
metabolite levels of 4-hydroxy-tamoxifen and N-desmethyl-tamoxifen quantified by LCMS/MS in the tumor tissue were 19.07, 3.97 and 33.64 ng/mg respectively (Figure II-7A).
This data indicates that the concentrations of tamoxifen needed to activate the AMPK
pathway in vitro are achievable in vivo. Tumors in mice treated with tamoxifen also had
significantly higher levels of phospho-AMPK and displayed downregulation of the mTOR
target phospho-4-EBP1 (figure II-7B and II-7C). These results are in agreement with the
tamoxifen-induced AMPK pathway activation seen in vitro.
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Figure II-7: Activation of the AMPK pathway by tamoxifen in vivo. A. Tamoxifen and
its metabolite levels in tumor tissue from 6 representative lysates following treatment of
nude mice bearing 4175 tumors with tamoxifen (100mg/kg) for 3 days analyzed by LCMS/MS. B. Representative Immunoblot of AMPK pathway activation in tumor lysates. C.
Densitometry analysis of signal intensity of Phos-AMPK normalized to total AMPK and
Phos-4EBP1 normalized to β-Tubulin. Data is the average ±SEM of N=17 per group,
*P<0.05 **P<0.01.

Discussion:
We have demonstrated that beyond its anti-estrogenic effects, tamoxifen exerts a
pronounced and immediate effect on tumor metabolism via a non-ER, mitochondrialspecific pathway. Specifically, through the inhibition of oxygen consumption upstream of
complex II, the increase in AMP/ATP ratio leads to activation of AMPK. We also
discovered a previously unreported dichotomy in the role of AMPK isoforms in tumor
survival following metabolic stress. Whereas AMPKα1 primarily appears to promote cell
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death through inhibition of the mTOR pathway and translation, AMPKα2 promotes
survival by a yet unidentified mechanism.
While the clinical benefit of tamoxifen in ER+ breast cancer patients has been
mainly attributed to inhibition of ER activity, tamoxifen has previously been shown to
have multiple effects independent of ER. We have further characterized the effects of
tamoxifen on mitochondria by describing the dose dependent effects on oxygen
consumption to occur independent of ER. We have also demonstrated that AMPK
activation occurs in both ER+ and ER- BC cells and that it is independent of ER signaling.
In addition, tamoxifen activated the AMPK pathway in an orthotopic model of triple
negative breast cancer. While we treated these animals for a short time at a high dose,
we would anticipate similar effects at a lower dose over a longer period of time, as
tamoxifen has been shown to accumulate in tumor tissues to levels up to 60-70 times
the plasma concentration 21.
The non-ER dependent effects of tamoxifen described here, have the potential to
expand the therapeutic window for tamoxifen into ER- BC and non-breast cancers.
Furthermore, most ER+ BC related deaths have been attributed to metastatic disease
which is often tamoxifen-resistant 6. While the mechanism by which tamoxifen resistance
occurs remains unclear, it is thought to involve alterations in ER itself and alterations in
the levels of co-regulators or downstream effectors in the signaling pathway 6. Our
results suggest that it would be valuable to further explore whether combination
therapies that take advantage of the metabolic effects of tamoxifen could restore
tamoxifen sensitivity or prevent resistance.
The precise target for tamoxifen in the mitochondrial respiration chain is not
currently clear. The evidence presented in this manuscript supports the hypothesis that
tamoxifen inhibits complex I in the electron transport chain. The ability of the complex II
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substrate succinate to restore oxygen consumption in tamoxifen treated cells points to
the inhibition of mitochondrial respiration upstream of complex II. Moreover, the inability
of complex I substrates glutamate and malate to restore any oxygen consumption in
permeabilized BC cells indicates that complex I may be the site of tamoxifen action.
However, we cannot completely rule out possible effects of tamoxifen on upstream
processes, such as the TCA cycle, that contribute electron donors to the respiratory
chain. Another implication of our findings with translational potential is the fact that
inhibition of oxygen consumption is a validated strategy to increase tumor pO2 and
decrease hypoxia, a major cause of cancer resistance to genotoxic therapy, including
radiation46. Therefore, tamoxifen has the potential to function as a radiation and
chemotherapeutic sensitizer. In fact, other complex I inhibitors, such as metformin, have
shown anti-cancer effects through both their metabolic effects and activation of
AMPK42,58. Although our results are reminiscent of the metabolic effects of metformin
treatment, both the inhibition of oxygen consumption and activation of AMPK occur at a
far more rapid rate (5-10 mins) than that seen with metformin (12-24 hrs). It is also
important to note that while in vitro metformin exerts its OXPHOS-inhibitory effects at
doses ranging from 1-50 mM, tamoxifen does so at low M concentrations.
The anti-tumorigenic effects of metformin in BC have been shown to be
dependent on its activation of AMPK 58. We asked if AMPK had a similar role in BC
survival of tamoxifen treatment. We used the CRISPR-cas9 system to delete AMPKα1
from MDA-MB-231 cells and observed a compensatory increase in AMPKα2 expression.
This would lead us to hypothesize that the isoforms have redundant effects, yet, we
observed opposing effects on cell survival. Other work examining the isoforms of
AMPKα has identified some differences, AMPKα2-/- mice exhibit mild insulin resistance
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and impaired glucose tolerance while AMPKα1-/- mice do not have a detectable
metabolic phenotype59,60 . At the molecular level, AMPKα2 has been shown to be more
reactive to AMP and is able to localize to the nucleus61. Moreover, AMPKα2 expression
has been shown to be suppressed in primary BC62. In our system, knock out of
AMPKα1 alone rescued cells from tamoxifen treatment while knock down of AMPKα2
increased cell death. Immunoblot analysis and [35S] labeling of proteins indicated that
the α1 subunit is responsible for downregulation of the MTOR pathway and translation.
However, both isoforms are needed to inhibit ACC and either isoform can activate
autophagy. We suspect that it is the loss of robust autophagy induction in the dual
AMPKα1α2 knockdown that results in increased tamoxifen cytotoxicity under those
conditions. The ability of tamoxifen to activate autophagy is well established63,64
however, the data reported here is the first to directly identify AMPK activation as a
mechanism of autophagy induction in tamoxifen treated BC cells.
In summary, we have described the ability of tamoxifen to inhibit oxygen
consumption via an ER-independent direct effect of mitochondria, upstream of complex
II. We have also shown that tamoxifen treatment results in robust AMPK activation and
identified AMPK as a mediator of tamoxifen toxicity through isoform specific effects.
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CHAPTER 3: Characterization of the effects of tamoxifen on glucose and fatty acid
metabolism and exploitation of the metabolic effects of tamoxifen for therapeutic
opportunities.

Sections of this chapter contribute to the published manuscript:

Natalie A. Daurio, Stephen W. Tuttle, Andrew J. Worth, Ethan Y. Song, Julianne M.
Davis, Nathaniel W. Snyder, Ian A. Blair, and Constantinos Koumenis. AMPK
activation and metabolic reprogramming by tamoxifen through estrogen receptorindependent mechanisms suggests new uses for this therapeutic modality in
cancer treatment. Cancer Res OnlineFirst March 28, 2016.
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Introduction:
Tamoxifen treatment has been reported to affect multiple metabolic processes.
These have included inhibition of mitochondrial function22,65,66, increased FDG-PET
signaling following treatment67–69, and altered lipid homeostasis including decreased
cholesterol levels4 and increased incidence of non-alcoholic fatty liver disease70. We
have shown that tamoxifen mediated inhibition of oxidative phosphorylation results in
metabolic stress characterized by an increase in AMP/ATP ratio and activation of the
AMPK pathway. Activation of AMPK functions to rebalance cellular energy charge by
turning off ATP consuming processes, including protein and fatty acid synthesis, and
turning on ATP generating processes such as glycolysis, autophagy and fatty acid
oxidation. As a result AMPK activation results in a significant reprogramming of cellular
metabolic processes. AMPK activation promotes glycolytic activity by increasing glucose
uptake through transporters GLUT171 and GLUT4 and activates glycolytic enzymes by
increased transcription of hexokinase II and direct phosphorylation of
phosphofructiokinase48,50. AMPK also shifts fatty acid metabolism from synthesis to
oxidation. This occurs through the phosphorylation and inhibition on acetyl CoA
carboxylase (ACC) the first committed step of fatty acid synthesis and through
decreased activity of SREBP1a, the transcription factor that controls gene expression of
many lipogenic enzymes including FASN, sterol-CoA desaturase 1 (SCD1) and
glycerol-3-phosphate acetyltransferase (GPAT)48,50.
In terms of metabolic targeted therapies, it has been postulated that concurrently
targeting adaptive responses to metabolic reprogramming can lead to significant
enhancement of the therapeutic window for multiple chemotherapeutic modalities72,73.
Therefore the combination of tamoxifen with other metabolically targeted agents may
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have therapeutic value. Moreover, oncogene activation results in increased dependence
on upregulated metabolic pathways. For example, both BRAF and KRAS mutations
promote glycolysis44,74. Resistance to targeted therapies limits the therapeutic options in
cancers such as melanoma and pancreatic cancer that are driven by these pathways.
The drug resistant populations are thus dependent on elevated OXPHOS and drugs that
target mitochondrial metabolism, including metformin, have potential utility in targeting
such resistant populations by synthetic-lethality approaches38,40,43,44.
Here, we characterize the changes in cellular metabolism that occur with
tamoxifen treatment. We show that tamoxifen treatment up regulates glucose uptake
and glycolysis and concurrent treatment with tamoxifen and glycolytic inhibitors result in
increased cell death. We also characterize the effects of tamoxifen on fatty acid
metabolism. In addition, we demonstrate that tamoxifen treatment is toxic to OXPHOS
addicted cancer cell populations.

Results:
AMPK activation is known to increase glycolytic activity in an attempt to restore
cellular ATP pools47. To investigate if this occurred following tamoxifen treatment, we
measured glucose uptake from the media in MDA-MB-231 and MCF7 cells. Glucose
uptake increased in a dose-dependent manner with tamoxifen treatment in both cell lines
(Figure III-1A). To examine if glycolysis was also upregulated by tamoxifen we analyzed
the incorporation of [13C] from [13C6]-Glucose into acetyl-CoA and lactate by LC-MS/MS.
Following tamoxifen treatment we observed an increase in [13C] labeling in these
products, indicating an increase in glycolytic activity (Figure III-1B and III-1C). The
activation of AMPK (P-AMPK) was enhanced under glucose deprivation conditions
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(figure III-1D) and treatment with the glycolytic inhibitor 2-deoxyglucose (2DG) (figure III1E) in both MCF7 and MDA-MB-231 cells, underscoring the importance of the glycolytic
switch for ATP generation during tamoxifen treatment.

Figure III-1: Tamoxifen treatment promotes glycolysis. A. Glucose uptake from media
following tamoxifen treatment for 1 hour in MCF7 and MDA-MB-231 cells. LC-MS/MS
13
analysis of C6-glucose metabolites after 30μM tamoxifen treatment for 1 hour in MDA-MB231 cells: Mass isotopomer analysis of B. Acetyl CoA and C. Lactate. N=4, **P<0.01
***P<0.001. D. Immunoblot analysis of phos-AMPK and total AMPK of cells treated with
20µM tamoxifen over time under glucose deprivation or 5mM glucose. E. Immunoblot
analysis of P-AMPK and total AMPK of cells treated with 20µM tamoxifen over time +/- 2DG.
F. Immunoblot analysis of LC3-I and LC3-II in BC cells after tamoxifen treatment.
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To investigate if glucose metabolism via the TCA cycle was altered with
tamoxifen treatment we looked at [13C6]-Glucose labeling of TCA cycle intermediates
citrate (Figure III-2A), malate (Figure III-2B), and succinyl-CoA (Figure III-2C). We
observed a very small increase in the labeled fraction of citrate and succinyl-CoA but not
of malate. While this data is statistically significant, the increase is very minor and is
likely not physiologically significant and indicates that glucose metabolism through the
TCA cycle is not changed with tamoxifen treatment. In addition to entering the TCA
cycle, the acetyl-CoA that is created from glucose as an end product of glycolysis can
also enter fatty acid metabolism pathways through conversion to malonyl-CoA by the
enzyme ACC. ACC is an AMPK target and phosphorylation of ACC by AMPK inhibits
enzyme function. ACC is the main AMPK target responsible for reduction of fatty acid
synthesis upon loss of intracellular ATP. We analyzed [13C]6-Glucose label
incorporation into malonyl-CoA following tamoxifen treatment and observed an increase
in labeled fraction in tamoxifen treated cells (Figure III-2D) indicating that a larger
amount of malonyl-CoA is derived from glucose following tamoxifen treatment. These
results were unexpected, given that AMPK activation should reduce malonyl-CoA
synthesis. However, with a large increase in glycolytic activity upon tamoxifen treatment
it is possible that the increase in malonyl-CoA labeled fraction from glucose is due to
substrate excess.
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Figure III-2: C6-Glucose labeling of TCA cycle intermediates and malonyl-CoA.
13
Isotopomer analysis by LC-MS/MS of [ C6]-glucose label incorporation into A. Citrate B.
malate C. succinyl-CoA and D. malonyl-CoA. Data are the average of four independent
experiments ±SEM *P<0.05 **P<0.01 ***P<0.001.

Since we demonstrated that tamoxifen blocks OXPHOS and concurrently
increases glucose uptake and utilization, it is likely that effective strategies for metabolic
targeted therapies may require the inhibition of both OXPHOS and glycolysis
simultaneously. 2DG, a non-metabolisable analog of glucose and 3-Bromopyruvate
(3BP), an alkylating agent and inhibitor of hexokinase-2 and glyceraldehyde 3phosphate dehydrogenase (GAPDH), induced a dose-dependent decrease in glucose
uptake, as expected (Figure III-3A and III-3C). More importantly, combined treatment
with relatively non-toxic doses of each of these inhibitors with tamoxifen significantly
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enhanced tamoxifen-induced cytotoxicity in MCF7 cells and in MDA-MB-231 cells
(Figures III-3B and III-3D). Notably, the sensitization to tamoxifen was larger in the MDAMB-231 cells, which display a higher basal rate of glucose uptake (Figure III-3A) and
lower basal level of OXPHOS (Figure II-1A).
We then tested if combination of tamoxifen with glycolytic inhibitors were
effective in reducing tumor growth in an in vivo model of triple negative breast cancer.
The MDA-MB-231 variant 4175 cells were injected orthotopically into the mammary fat
pad. Mice were randomized into four groups: vehicle control, tamoxifen only, 3BP only
and tamoxifen plus 3BP. Two weeks after tumor implantation, mice were given a loading
dose of tamoxifen, followed by a maintenance dose of 25 mg/kg every 3 days. 3BP was
given daily at 5mg/kg. Tumor growth was monitored twice weekly for 35 days. While the
treatment was tolerable, no difference in tumor growth was seen between any treatment
groups and control mice (Figure III-3E). Multiple factors may be responsible for the lack
of efficacy seen in this model. Dose limiting toxicity of 3BP was significant; therefore, it
may be that the tolerable dose was not high enough to reduce glycolysis in the tumor.
Moreover, tumor growth in this model is quite slow, and may be that the metabolic stress
induced by this treatment combination would be effective in a more aggressive model.
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Figure III-3: Tamoxifen treatment synergizes with glycolysis inhibitors. A. Glucose
uptake measurements in BC cells treated with 2DG. B. Survival of BC cells treated with
2DG and tamoxifen or tamoxifen alone. C. Glucose uptake measurements in BC cells
treated with 3-BP. D. Survival of BC cells treated with 3-BP and tamoxifen or tamoxifen
alone. Data are the average of three independent experiments ±SEM *P<0.05 **P<0.01
***P<0.001. E. Measurements of 4175 tumor volume ±SEM over time in in nude mice
treated with vehicle control, 3BP only, Tamoxifen only, or both 3BP and Tamoxifen. N=20
per group.
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Synthesis of fatty acids (FAs) which begins with the synthesis of malonyl-CoA
from acetyl-CoA, are of particular importance in cancer due to the need to generate
excess membranes for rapid proliferation. Moreover, the oxidation of FAs in the
mitochondria can replenish cellular ATP levels during times of metabolic stress75. To
examine if tamoxifen impacted FA metabolism, we performed metabolite analysis of fatty
acyl-CoA species by LC-MS/MS. The analysis showed an accumulation of acetyl-CoA
and malonyl-CoA following tamoxifen treatment (Figure III-4A). We also observed a
reduction in succinyl-CoA and other medium chain acyl-CoA species (C3:0, C6:0)
consistent with reports of the effects of other complex I inhibitors76 and an accumulation
of longer chain (C16-C20) acyl-CoA species (Figure III-4A). The addition of [13C]-glucose
or [13C]-glutamine resulted in no labeling of the long-chain CoA metabolites, indicating
that these fatty acyl-CoAs are not synthesized from glucose or glutamine de novo in
response to tamoxifen treatment. It has been reported that under metabolic stress, cells
switch from glucose and glutamine to acetate as a carbon source for fatty acid
synthesis77. Indeed, upon tamoxifen treatment, labeling from [14C]-acetate of the cellular
lipid fraction increased (Figure III-4B).
Activation of the AMPK pathway is also known to promote β-oxidation of fatty
acids as a strategy to increase ATP pools. The degradation of lipid droplets by
autophagy, termed lipophagy, increases the supply of free FAs which are then
transported into the mitochondria for oxidation75. We also observed a rapid activation of
autophagy upon tamoxifen treatment (Figure III-1F). BODIPY 493/503 stain, which
measures total neutral lipid content in the cell, decreased in cells treated with tamoxifen
(Figure III-4C). These data suggest that the accumulation of the long chain acyl-CoA
species results from breakdown of lipid droplets.
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To further probe the role of fatty acid metabolism in the cellular response to
tamoxifen treatment we supplemented the cell culture media with oleic acid conjugated
BSA. Supplementation with oleic acid completely rescued MDA-MB-231 cells from
tamoxifen cytotoxicity (Figure III-4D). Moreover, oleic acid restored mTOR activity as
determined by immunoblot (Figure III-4E). However, oleic acid supplementation was not
sufficient to inhibit AMPK phosphorylation upon tamoxifen treatment.
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Previous page-Figure III-4: Tamoxifen alters fatty acid metabolism: A. LC-MS/MS
metabolomic analysis of acyl-CoA species in MDA-MB-231 cells with and without
14
tamoxifen treatment. B. quantification of C-acetate radiolabel incorporation into total
cellular lipid fraction. C. Flow cytometry quantification of BODPIY 493/503 stain intensity
and representative images of BODIPY staining in control and tamoxifen treated MDA-MB231 cells. D. Effect of oleic acid supplementation on the survival of MDA-MB-231 cells
treated with tamoxifen. E. Immunoblot of the effect of oleic acid supplementation on
tamoxifen inhibition of the mTOR pathway in MDA-MB-231 cells. Data is the average of
three independent experiments +/- SEM. *P<0.05, **P<0.01, ***P0.001.

Acquired resistance to BRAF inhibitors in melanoma was recently shown to
elevate oxygen consumption rate in the resistant cell population40. Therefore, we tested
the effects of tamoxifen as a treatment in an in vitro model of OXPHOS addiction in
cancer. We confirmed the previously reported increase in oxygen consumption rate in
melanoma cells WM9 and 1205Lu selected over 3 days for a population that was
resistant to the BRAF inhibitor PLX4720 (Figure III-5A and III-5B). We observed that
tamoxifen inhibited oxygen consumption in this resistant population as well as the
parental melanoma cell lines (Figure III-5A and III-5B). Tamoxifen induced cytotoxicity
was then determined in the PLX4720 resistant population and the parental melanoma
cell lines. The PLX4720-resistant population was more sensitive to tamoxifen (Figure III5C and III-5D). Collectively, this data strongly suggests that tamoxifen can be used in
combination with other therapies to effect robust anti-tumor effects via metabolic stress.

Next Page - Figure III-5: Tamoxifen inhibits OXPHOS and is cytotoxic to BRAFInhibitor resistant melanomas. BRAF mutant melanoma line WM9 and 1205Lu were
treated with BRAF inhibitor PLX4720 for three days to select for a resistant population. A.
Oxygen consumption measurements of the PLX4720 resistant population and the
parental melanoma cell lines WM9 and B. 1205Lu treated with tamoxifen. C. Survival of
the PLX4720 resistant population and the parental melanoma cell lines WM9 and D.
1205Lu treated with tamoxifen. Data is the average of three independent experiments +/SEM. *P<0.05, **P<0.01, ***P0.001.
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Discussion:
We have demonstrated that tamoxifen treatment increases glycolysis and cellular
dependence on glycolytic activity for cell survival. This can be exploited for therapeutic
benefit via combination treatment with tamoxifen and glycolytic inhibitors. We have also
shown that tamoxifen alters cellular fatty acid metabolism through inhibition of fatty acid
synthesis and depletion of intracellular lipid stores. Supplementation with fatty acids can
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rescue cells from tamoxifen treatment, highlighting the importance of fatty acid oxidation
under tamoxifen treatment conditions.
Tamoxifen inhibition of oxygen consumption results in an increase in the cellular
AMP:ATP ratio and the activation of the AMPK signaling pathway and an increase in
glycolytic activity. Other activators of AMPK, such as metformin, have also been shown
to increase dependence on glycolysis. Intriguingly, soon after BC patients begin
treatment with tamoxifen, a “metabolic flare” is often seen in their FDG-PET scans67,69.
Although the cause for this radiologic abnormality has not been clearly delineated, it is
reasonable to hypothesize that this could be due to increased uptake of FDG in
response to metabolic reprogramming and AMPK activation, since GLUT 1 transporters,
the major transporter system of glucose and FDG uptake, are AMPK targets71.
We have also demonstrated the potential for increased therapeutic benefit
through drug combinations with tamoxifen that have a synergistic effect via blockade of
upregulated metabolic pathways. Glycolytic inhibitors have long been attractive clinical
agents due to the Warburg effect, yet systemic toxicity has limited their success in the
clinic. 2DG has been tested in clinical trials and 3BP has shown significant preclinical
potential78 .Our data suggests that clinical use of these inhibitors in combination with
tamoxifen may result in increased efficacy and use of reduced doses that may limit
toxicity.
While tamoxifen synergized with glycolytic inhibitors in vitro, combined treatment
with tamoxifen and 3BP did not impact tumor growth in an in vivo model of triple
negative breast cancer. The lack of efficacy in vivo may be due to multiple factors. First,
3BP is quite toxic and it is possible that the tolerated dose was not high enough to
significantly reduce glycose metabolism in tumors. Tamoxifen has also been reported to
inhibit of angiogenesis79 which may further reduce drug delivery to the tumor. Tamoxifen,
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a highly lipophilic drug, was delivered in peanut oil. Our in vitro data has shown that
supplementation with fatty acids can rescue cells from tamoxifen cytotoxicity. Therefore,
using lipids as the drug vehicle may have countered the effects of tamoxifen treatment or
available fatty acids from circulation or tumor microenvironment may have also
contributed to the lack of efficacy. Another possible explanation for the lack of in vivo
efficacy may be the chosen tumor model. Rodent triple negative BC models progress
quite slowly and it may be that the tumor can tolerate more metabolic stress due to low
proliferation rate. It would be worthwhile to test the combination of tamoxifen and
glycolytic inhibition in a more aggressive tumor model.
Our results are also in agreement with other metabolic effects of tamoxifen in
patient populations. Women on tamoxifen therapy have an increased risk for developing
non-alcoholic fatty liver disease70. However, the effects of tamoxifen on tumor fatty acid
metabolism have not been investigated in detail. Accumulation of malonyl-CoA following
tamoxifen treatment has been previously reported80 and we also observed this in BC
cells. The synthesis of malonyl-CoA is the rate-limiting step in fatty acid synthesis, thus
its accumulation leads us to suspect that there is a decrease in the activity of FASN
which is consistent with AMPK activation. It is also possible that increased upstream
flux, through glycolysis and acetate utilization, contributes to the accumulation of
malonyl-CoA with tamoxifen treatment. It is worth noting that AMPK is also known to
inhibit fatty acid synthesis and promote β-oxidation, primarily through inhibiting ACC47.
Metabolic labeling indicates that acetate and not glucose or glutamine functions as the
carbon source for fatty acid synthesis during tamoxifen treatment. The propensity for
cells to switch to acetate utilization under metabolic stresses including hypoxia and
nutrient deprivation has been previously reported77 and it is not surprising that it occurs
under tamoxifen-generated metabolic stress as well.
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Depletion of intracellular lipid stores and accumulation of long chain fatty acylCoAs are consistent with an increase in beta oxidation which is also expected under
AMPK activation conditions. Due to the robust activation of autophagy we previously
described under tamoxifen treatment we suspect that lipophagy plays a significant role in
replenishing or maintaining ATP during metabolic stress via the release of free fatty
acids from lipid droplets75. It is important to note that β-oxidation generates both NADH
and FADH2. Under conditions of complex I inhibition, the FADH2 generated via oxidation
of fatty acids could feed into electron transport via complex II, similar to what is seen
with the addition of succinate, to power ATP synthesis. The ability of oleic acid to rescue
translation as well as survival highlights the dependence of tamoxifen treated BC cells
on fatty acid metabolism for survival.
Interestingly, malonyl-CoA is known to inhibit carnitine palmitoyltransferase
(CPT-1), the transporter responsible for transporting free fatty acids into the
mitochondria for β-oxidation. As a result, it would be expected that β -oxidation would be
decreased under tamoxifen treatment conditions due to the large accumulation of
malonyl-CoA. Therefore it is possible that the ability of oleic acid to rescue tamoxifen
treatment is not due to providing a substrate for ATP generation via β-oxidation but
through providing fatty acids for membrane generation as tamoxifen has been reported
to accumulate in lipid bilayers and likely damage cellular membranes. More experiments
would be required to investigate the effects tamoxifen has on cellular membranes and
whether oleic acid supplementation contributes to membrane repair.
Recognition of cancer as a heterogeneous disease has led to the development of
personalized medicine and targeted therapies. Drugs designed to inhibit specific
activated oncogenes often have early success, but are plagued by the emergence of
resistance. If the pathways that contribute to resistance can be identified and inhibited, it
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is reasonable to infer that resistance may be prevented or delayed. Resistance to BRAF
and KRAS target therapies has been described to require increased dependence on
OXPHOS. Our data shows that tamoxifen mediated inhibition of OXPHOS in this
resistant population results in increased cell death. Therefore, the combination of
tamoxifen with these targeted therapies may increase clinical response.
In conclusion, we have characterized the impact of tamoxifen treatment on
glucose and fatty acid metabolism. These metabolic changes highlight pathways that
may be essential for cell survival of tamoxifen treatment. We have demonstrated that
glycolytic activity is required in tamoxifen treated cells and combination of tamoxifen and
glycolytic inhibitors may be an effective therapeutic strategy. Additional in vivo models
would be necessary to further test this hypothesis. Moreover, OXPHOS addiction is
characteristic of resistance to BRAF and KRAS targeted therapies and tamoxifen
inhibition of respiration is preferentially cytotoxic to this population and may be of clinical
use to overcome resistance.
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CHAPTER 4: Conclusions and Future Directions
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Chapters II and III collectively describe a novel mechanism of action for tamoxifen, an
extensively used drug for ER+ BC treatment (Figure IV-1). Tamoxifen inhibits oxygen
consumption at complex I of the mitochondrial respiratory chain resulting in a decrease
in oxygen consumption and increase in the intracellular AMP/ATP ratio. AMPK
activation impacts cell survival through isoform specific downstream signaling.
Tamoxifen treatment also results in an increase in glycolysis as well as alterations in
fatty acid metabolism including break down of neutral lipid droplets, accumulation of long
chain fatty acyl-CoAs, and an increase in acetate utilization (Figure IV-1). These
metabolic effects of tamoxifen suggest strategies by which clinical efficacy may be
increased through synergy with pharmacological targeting of upregulated metabolic
pathways.
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Previous page – Figure IV-1: Model of the effects of Tamoxifen on metabolism. Tamoxifen
inhibits oxygen consumption at complex I of the mitochondrial electron transport chain. This
increases the AMP/ATP ratio and activates AMPK. Downstream effects of AMPK activation
on cell survival, translation and autophagy are mediated in an isoform specific manner.
Tamoxifen treatment also increases cellular dependence on glycolysis and alters fatty acid
metabolism.
Tamoxifen inhibition of Oxygen consumption
Chapter II describes a novel mechanism by which tamoxifen treatment inhibits
cellular oxygen consumption. Tamoxifen acts directly on the mitochondria, upstream of
complex II, independently of ER signaling. We see inhibition of oxygen consumption
across a panel of multiple cancer cell lines, therefore these effects have the potential to
expand the use of tamoxifen beyond ER+ BC. Through degradation of ERα by
fulvestrant and knock out using CRISPR-cas9 we have demonstrated that ERα signaling
does not contribute to the effects of tamoxifen on respiration. However, the impact of
ERβ signaling on tamoxifen inhibition of oxygen consumption was beyond the scope if
this work. ERβ and ERα have both overlapping and distinct biological functions. ERβ is
expressed in breast tissue but has been reported to be downregulated in BC due to
promotor methylation, suggesting it may function as a tumor suppressor. However
immunohistochemical staining shows ERβ expression in approximately 2/3 of BC
samples81. Tamoxifen functions as an ERβ antagonist82 but the role of ERβ in
response to therapy remains unclear. ERβ expression is correlated with improved
survival83 but has also been shown to be increased in tamoxifen resistant cases84.
Important for elucidating the metabolic effects of tamoxifen is the reported expression of
ERβ in mitochondria85,86. While we did not test whether ERβ signaling contributes to the
ability of tamoxifen to alter respiration, it is unlikely. Inhibition of oxygen consumption
occurs within 2 minutes of the addition of tamoxifen, indicating that these effects are
likely not the result of transcriptional changes promoted by nuclear receptors. However,
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more experiments would be needed to determine if ERβ contributes to the effects of
tamoxifen on BC cell metabolism.
This study suggests that tamoxifen is an inhibitor of electron transport chain
complex I. Complex I inhibitors have become of particular interest as cancer
therapeutics due to the anti-cancer properties of metformin, a reported complex I
inhibitor42. However, many complex I inhibitors such as rotenone are highly toxic. Our
data demonstrates that tamoxifen inhibits oxygen consumption faster and at lower doses
than metformin. The data reported in this study as well as numerous clinical trials
demonstrating the safety of tamoxifen at a large range of dosages support the clinical
use of tamoxifen as a safe and well tolerated complex I inhibitor. However, we cannot
completely rule out other mitochondrial targets. Previous studies have reported
tamoxifen to alter the mitochondrial membrane potential23,65 and inhibit at complex III87.
While our data does not support these mechanisms, future studies such as binding
assays and crystallography would be necessary to determine the exact interaction site of
tamoxifen with mitochondria.
The many phase I/II clinical trials that explored high dose tamoxifen as a single
agent or in combination with cytotoxic chemotherapeutics demonstrated safety, but little
clinical efficacy. Our in vitro data suggests that tamoxifen treatment may be effective in
combination with other metabolically targeted agents, such as glycolytic inhibitors.
Moreover, this study also suggests that tamoxifen may be effective in combination with
oncogene targeted therapy. Future work would be necessary to demonstrate the efficacy
of these combinations in vivo. It would also be worthwhile to investigate the ability of
tamoxifen to function as a radiosensitizer. Tumor hypoxia significantly limits the success
of radiotherapy for cancer treatment. The presence of intracellular oxygen enhances the
effect of radiation induced DNA damage through the “oxygen effect”. Ionizing radiation
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results in the generation of carbon centered radicals in DNA and proteins which can be
repaired by hydrogen donors in the cell, a process known as chemical restitution. In the
presence of oxygen, peroxidation of radicals occurs in a process known as damage
fixation. These peroxy radicals cannot be repaired, resulting in increased DNA damage
and cell death88. To date, strategies to reduce hypoxia for radiosensitization have not
achieved regular clinical use. An agent that decreases tumor oxygen consumption has
the potential to act as a radiosensitizer or enhancer because it would increase local pO2
and reduce hypoxia46. Such compounds including metformin89, nelfinavir90, and
PI3K/mTOR inhibitors91 have been shown to reduce hypoxia and radiosensitize tumors.
Atovoquone, an anti-malarial drug that targets mitochondrial electron transport complex
III92, is also in clinical trials as a radiosensitizer. In addition to reducing oxygen
consumption, metformin has also been shown to act as a radiosensitizer through AMPK
dependent mechanisms93,94. Based on this literature and the data described in this
study, it would be reasonable to hypothesize that tamoxifen would reduce tumor hypoxia
and function as a radiosensitizer. Additional experiments in vitro and in vivo are needed
to test this.

Tamoxifen activation of AMPK
Chapter II describes tamoxifen as a novel activator of AMPK. Tamoxifen
treatment results in an increase in the AMP/ATP ratio and phosphorylation of AMPKα.
Activation of AMPK by tamoxifen further supports the hypothesis that tamoxifen acts as
a complex I inhibitor as well as the use of tamoxifen as a metabolically targeted
therapeutic. Multiple kinases have been reported to phosphorylate AMPK. In this study
we explored the role of the two most prominent AMPK-Kinases, LKB1 and CaMKK2 in
the mechanism by which tamoxifen activates AMPK. Using both genetic and
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pharmacological means, we determined that both kinases play a role in AMPK activation
following tamoxifen treatment and that their prominence is largely cell type dependent.
CaMKK2 has been shown to phosphorylate AMPK in response to AICAR treatment in
cells lacking LKB195. However, CaMKK2 also activates AMPK in response to an
increase in intracellular calcium concentrations96. Therefore, the role of CaMKK2 in
activation of AMPK following tamoxifen treatments poses the question of whether
calcium dysregulation by tamoxifen may also be involved. Tamoxifen has been
previously shown to alter calcium signaling in BC and glioma cells97. In order to
determine if this effect is involved in activation of AMPK, chelators such as BAPTA-AM
could be used. AMPK is also allosterically activated by AMP binding, even without
phosphorylation of the AMPKα56, our data agrees with these reports as we see
phosphorylation of ACC with tamoxifen treatment even without phosphorylation of
AMPK.
The role of AMP allosteric activation of AMPK as well as the involvement of
CaMKK2 in tamoxifen-mediated activation of AMPK is important to note because LKB1
is a tumor suppressor and is frequently lost in cancers. Recent studies have shown that
phenformin is effective as a single agent in a mouse model of KRAS LKB1-/- NSCLC,
suggesting that AMPK activators may be therapeutic in LKB1-/- cancers98. Thus our data
suggests that tamoxifen treatment may also be effective in these cancers.
Chapter II describes the role of AMPK in BC cell survival of tamoxifen treatment
to be mediated by isoform specific effects. We see protection from tamoxifen mediated
cytotoxity in CrspAMPKα1 knock out cell, while loss of AMPKα2 results in increased cell
death. In our system, both isoforms are needed to inhibit ACC, while inhibition of the
mTOR pathway is AMPKα1 dependent, yet activation of autophagy can be promoted by
either isoform. Upon loss of AMPKα1 we see increased AMPKα2 expression and it
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remains unclear whether it is the loss of AMPKα1 or overexpression of AMPKα2 that
rescues cells from tamoxifen. Moreover, it is still unclear which downstream targets are
responsible for the survival effects of each isoform and more work would be needed to
elucidate these specific mechanisms. While this work identifies potentially novel isoform
specific roles for AMPKα in mediating downstream signaling effects, it is important to
recognize that these differences may be both cell type dependent as well as stress
dependent. More work would be needed to determine reproducibility across multiple
contexts.

Tamoxifen alters glucose and fatty acid metabolism
Chapter III aims to characterize the metabolic changes that accompany
tamoxifen inhibition of OXPHOS. It is well established that inhibition of respiration results
in an upregulation of glycolytic activity and this effect is seen in tamoxifen treated BC
cells as well. Using [13C6]-glucose labeling we see the contribution of glucose carbons to
lactate, acetyl-CoA, and malonyl-CoA to be increased with tamoxifen treatment.
However we do not see a significant change in labeled-glucose incorporation into the
TCA cycle. Inhibition of OXPHOS is often correlated with a reduction in TCA cycle
activity due to the buildup of NADH and FADH2. This study did not examine total levels
of TCA cycle intermediates, therefore it is possible that tamoxifen reduces overall TCA
cycle activity, without any change in the percent labeling from glucose. It would be
important to further examine the effects of tamoxifen on TCA cycle activity as many of
the intermediates can be used for synthesis of other essential macromolecules such as
amino acids and nucleotides99,100. Moreover, investigating whether there is any change
in the NAD+/NADH and FAD/FADH2 levels upon tamoxifen treatment would also be
worthwhile. Further examination of TCA cycle activity, amino acids and nucleotide
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synthesis pathways, as well as reducing equivalents upon tamoxifen treatment could
potentially identify opportunities to increase tamoxifen response by targeting these
altered pathways.
Chapter III also reports significant changes in fatty acid metabolism upon
tamoxifen treatment. Acyl-CoA quantification showed an unexpected accumulation of
long chain CoA species. Labeling experiments indicated that these were not synthesized
de novo from glucose or glutamine and accumulation of malonyl-CoA suggests an
inhibition of FASN. Loss of total neutral lipid content in the cell suggests the source of
these free fatty acids to be break down of lipid droplets. However, we did see an
increase in acetate label incorporation into the total lipid pool upon tamoxifen treatment.
Yet this experiment did not identify what species of lipids were labeled with 14C acetate,
nor did it quantify the total levels of any species. As a result the interpretation of this data
is quite limited. It suggests that BC cells treated with tamoxifen shift the fatty acid carbon
source from glucose or glutamine to acetate, which is in agreement with previous reports
of cells under metabolic stress77. Further investigation into cellular acetate metabolism
with LC-MS/MS analysis of

13

C acetate labeling into the acyl-CoAs would provide

additional clarity. Moreover, if acetate utilization is required in tamoxifen treated cells,
ACSS2, the enzyme that converts acetate to acetyl-CoA may be a good target to
increase tamoxifen efficacy.
Supplementation of BC cells with oleic acid completely rescues cells from
tamoxifen treatment and restores mTOR activity. It is easy to hypothesize that these
effects are due to β-oxidation generation of ATP and macromolecular intermediates.
However, elevated malonyl-CoA levels seen with tamoxifen treatment suggest that the
CPT-1 transporter is inhibited. Therefore β-oxidation would be blocked under these
conditions. LC-MS/MS analysis of 13C labeled oleate incorporation into short chain Acyl55

CoA’s would provide insight into whether oleic acid undergoes β-oxidation. Another
possible explanation for the pro-survival effects of oleic acid on tamoxifen treated cells
could be the use of oleic acid to repair damaged membranes. Tamoxifen has been
shown to accumulate in, and alter the properties of cellular membranes101,102. More
experiments would be needed to assess the extent to which intracellular membranes are
compromised by tamoxifen treatment and if oleic acid plays any role in repair.

Therapeutic opportunities exploiting the metabolic effects of tamoxifen
Metabolic flexibility allows for the upregulation of pathways to compensate for a
physiological or pharmacological blockade. This plays a role in ability of cancer cells to
survive nutrient deprivation characteristic of the tumor microenvironment as well as
limited the use of metabolically targeted agents. It has been postulated that dual
targeting of these compensatory pathways would improve the efficacy of metabolically
targeted therapeutics
Our data suggest that combination treatment with tamoxifen and glycolysis
inhibitors may be clinically effective, however in an in vivo mouse model of triple
negative BC, we did not see any effect on tumor growth with tamoxifen and the glycolytic
inhibitor 3BP. The lack of efficacy in vivo may be due to multiple factors including the
resistance of slowly proliferating tumors to metabolic stress, delivery of tamoxifen in a
lipid vehicle, and dose limiting toxicity of 3BP. Additional studies are warranted to
determine if this combination treatment could be effective in reducing tumor growth in
other models. The development of improved glycolytic inhibitors is also greatly needed.
No available glycolytic inhibitors have reached regular clinical use despite being
extensively studied. Limitations to the development of such compounds include the

56

ubiquitous expression of glycolytic enzymes in all tissues and the dependence of
sensitive organs such as the brain on glucose metabolism31,103.
Chapter III also describes the success of tamoxifen as a treatment in OXPHOS
addicted tumor cell populations. Inhibition of oncogenes that promote the Warburg effect
by targeted therapies result in increased respiration in resistant populations. These
resistant populations result in therapeutic failure and disease progression in patients.
Using a model of BRAF-inhibitor resistant melanoma, treatment with tamoxifen can
reduce oxygen consumption preferentially kill the resistant cells. We hypothesize that
the increased cell death is due to the inability of these cells to respire in the presence of
tamoxifen and the ensuing metabolic stress. However we have not determined the exact
mechanism by which tamoxifen results in cytotoxicity in this population. More
experiments would be necessary to determine if loss of ATP and activation of AMPK,
loss of reducing equivalents and an increase in ROS, as well as inability of these cells to
synthesize macromolecular intermediates contributes to cell death. In addition,
Investigating whether this effect occurs in vivo would be necessary to determine whether
the addition of tamoxifen treatment to BRAF-inhibitors improves survival and reduces
recurrence in melanoma.
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CHAPTER 5: Materials and Methods
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Chemicals and antibodies. Tamoxifen, fulvestrant, methyl succinate, STO609, oleic
acid-BSA were purchased from Sigma Aldrich. The following rabbit polyclonal Antibodies
were obtained from Cell Signaling: AMPKα, AMPKα1, phos-AMPKα, LKB1, phos-ACC,
ACC, Phos-p70s6K, phos-s6, phos-4EBP1, cleaved PARP, cleaved caspase 3, and
LC3B. ERα antibody purchased from Genetex. AMPKα2 antibody purchased from
Millipore. siRNA against PRKAA2, LKB1 and CaMKK2 was purchased from Dharmacon.

Cell culture. Cell lines were cultured in Dulbecco’s modified eagles medium (DMEM)
supplemented with 10% FBS, 1% penicillin/streptomycin, and HEPES at 37°C humidified
5% CO2 atmosphere. MCF7, MDA-MB-231 and 4175 cell lines were a gift from Andy
Minn. LCC1 cells were a gift from Robert Clarke. WM9 and 1205Lu cells were a gift
from Meenhard Herlyn (Wistar Institute). Cell lines were authenticated through genetic
testing by ATCC.

Oxygen consumption measurements. Oxygen consumption was measured using a
YSI 5300a Biological oxygen monitor. Electrodes were equilibrated in media for 10
minutes. Cells were trypsinized and suspended at 2x107cells per mL and injected into
the chamber at a 1:10 dilution. After oxygen consumption rate was recorded, drug was
injected into the chambers at 10 µM increments, allowing consumption rate to be
determined after each injection. Total protein per chamber was quantified by Lowry
assay.

Isolation of liver mitochondria. The liver was removed from a sacrificed mouse and
homogenized in 8 volumes of sucrose buffer (0.25 M sucrose, 0.02 M KCl, 0.005 M
MgCl2, 0.01 M KH2PO4 ( pH= 7.4). The homogenate was spun at 600 x g for 5 min at
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4°C. The supernatant was then transferred to a new tube and centrifugation was
repeated. Cleared supernatant was spun at 9000 x g for 10 min at 0°C and the pellet
was resuspended in sucrose buffer. The following conditions were used for respiration
measurements: Complex 1 respiration: Sucrose buffer + 0.1 mM ADP, 5 mM glutamate
and 5 mM malate. Complex 2 respiration: Sucrose buffer + 0.1 mM ADP and 5 mM
sodium succinate.

Respiration of permeabilized cells. BC cells were trypsinized and washed once with
sucrose buffer. Cells were diluted to 2x106 cells per mL in sucrose buffer and digitonin
was added at 25ug/mL and incubated at room temperature for 2 minutes,
Permeabilization was confirmed with trypan blue stain. Oxygen consumption
measurements were performed as described for liver mitochondria.

Cell survival assays. Modified MTT assay: Cells were plated in a 24 well plate at 5x104
cells per well and allowed to attach overnight. After drug incubation, cells were washed,
re-fed with fresh media and grown for 5-7 days until control cells reached confluency. An
MTT assay kit (Roche) was used to measure survival and proliferation following the
manufacturer’s instructions. Clonogenic survival assay: Cells were plated at 80%
confluency in 60mm dishes and allowed to adhere overnight. Cells were treated with
experimental conditions, trypsinized, washed, re-plated at low density (100-1000 cells)
and incubated until visible colonies grew from single cells. Colonies stained with crystal
violet and counted. Survival was reported as fraction of colony count over number of
cells plated, normalized to control conditions.
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Immunoblot analysis. Cells were lysed using nonident p-40 buffer (1% NP-40, 1 mM
phenylmethylsulfonyl fluoride, 1X Complete Mini protease inhibitor cocktail [Roche], 1X
phosphatase inhibitor cocktail 2 [Sigma] in PBS.) Protein concentrations of lysates were
determined using DC protein assay (BioRad). Equal amounts of protein were resolved
on sodium dodecyl sulfate polyacrylamide gels and transferred to polyvinylidene fluoride
membranes. Membranes were blocked with 5% non-fat dried milk in TBS-T (20 mM Tris,
137 mM NaCl, 0.1% Tween-20; pH 7.6) and then incubated in primary antibody followed
by secondary antibody. Proteins were visualized by incubating membranes in ECL
chemicals and exposing to film.

Generation of CRISPR-Cas9 knockout cell lines. Knock out cell lines were generated
using the CRISPR-cas9 system as previously described104. sgRNAs were designed to
target the first exon of the genes of interest using the CRISPR design tool at
http://crispr.mit.edu/. Two sgRNA sequences were chosen for each gene of interest (See
table below). Briefly, sgRNA’s were cloned into CRISPR-cas9 plasmid. pSpCas9(BB)2A-Puro (PX459) was a gift from Feng Zhang (Addgene plasmid # 48139) . Cells were
transfected using lipofectamine 2000 and carrier DNA. Media was changed 24hrs after
transfection and cells were selected with puromycin for 48 hrs. Remaining cells grown
up and clones were selected. Clones were screened for gene excision or mutation by
DNA gel and expression of the protein of interested by western blot. Knock out was
successful using both PRKAA1 sgRNAs 1 and 2. Knock out of ESR1 expression
required combined transfection of sgRNA 1 and 2.
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Table V-1: sequences of sgRNA for CRISPR-cas9 knock out cell lines

HPLC quantification of AMP and ATP. AMP and ATP quantified using a previously
published method 105. Briefly, 2-4x106 cells were plated in 10cm2 dishes and treated with
tamoxifen. Cells were then pelleted and nucleotides extracted with perchloric acid.
Extracts were analyzed by ion pair reverse phase HPLC. Analysis was carried out on a
Jasco HPLC. Separation was performed on SUPELCOSIL C18 column (15 cm x 4.6
mm, 3 µm particle size) in combination with a Supelguard Acentis C18 guard column (2
cm x 4.0 mm) from Sigma.

LC-MS/MS metabolite analysis. Liquid chromatography-selected reaction monitoring
(LC-SRM)/MS was used for analysis of acyl-CoA thioesters. Methods were previously
described in detail106. CoAs were separated using a reversed-phase HPLC
Phenomenex Luna C18 column (2.0 mm × 150 mm, particle size 3.5 μm) with 5 mM
ammonium acetate in water as solvent A, 5 mM ammonium acetate in ACN/water (95:5;
v/v) as solvent B, and ACN/water/formic acid (80:20:0.1; v/v/v) as solvent C. Samples
were analyzed using an API 4000 triple-quadrupole mass spectrometer (Applied
Biosystems, Foster City, CA) in the positive electrospray (ESI) mode. Samples (10 μL)
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were injected using a Leap CTC autosampler (CTC Analytics, Switzerland) where they
were maintained at 4 °C.

Short-chain and Long-chain acyl-CoA extraction. Short-chain acyl-CoA extraction.
Extractions were performed as described in detail previously106. Briefly, cells were lifted
manually with a cell scraper, centrifuged at 500 x g for 5 min and resuspended in 1 mL
of ice-cold 10% TCA and pulse-sonicated for 30 s on ice using a sonic dismembranator
(Fisher), followed by a 5 min centrifugation at 15,000 x g. The supernatant was
transferred to a fresh tube, and the pellet was discarded. The supernatant was purified
by solid-phase extraction as follows: Oasis HLB 1 cm3 (30 mg) SPE columns (Waters)
were conditioned with 1 mL of methanol followed by 1 mL of water. The collected
supernatant was applied, washed with 1 mL of water, and finally eluted using three
subsequent applications of 0.5 mL of methanol containing 25 mM ammonium acetate.
Eluted compounds were dried down under nitrogen and resuspended in 100 μL of 5% 5SSA. For isotopologue analysis, the same extraction was used, except that no internal
standard was added. Long-chain acyl-CoAs extraction- Extractions were performed as
described in detail previously107. Cells were lifted manually with a cell scraper,
centrifuged at 500 x g for 5 min and resuspended in 550 µL/10 cm2 plate of ACN:IPA
(3:1; v/v). The internal standard prepared using stable isotope labeling by essential
nutrients in cell culture (SILEC) was added (200 µL) and samples were pulse sonicated
with a probe tip sonicator on ice 30 times for 0.5 s. 250 µL of 100 mM KH2PO4 (pH 6.7)
was added to the samples, then vortex-mixed and spun down for 10 min at 16,000 x g at
4°C. The supernatant was transferred to a glass tube and acidified with 125 µL of
glacial acetic acid. SPE columns were equilibrated with 1 mL of ACN/IPA/water/acetic
acid (9:3:4:4; v/v/v/v) washing solvent. Samples were transferred to the columns, which
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were washed two times with 1 mL of the washing solvent. The acyl-CoAs were then
eluted by washing the columns twice with 500 µL methanol/250 mM ammonium formate
(4:1; v/v) into glass tubes. After evaporation to dryness under nitrogen gas, the eluates
were re-dissolved in 50 µL of water/ACN (7:3; v/v) containing 5 % SSA (w/v) and
transferred to HPLC vials for LC-SRM/MS analysis.

Lactate extraction and analysis by LC-MS/MS: Media was aspirated and cells were
quenched by the direct addition of 1 mL -80 °C 4:1 methanol:water (v/v) to the cell
culture dish. Plates were placed at -80 °C for 20 min then scraped and transferred into
Eppendorf tubes. Samples were pulse sonicated on ice for 30 sec at a rate of 1
pulse/sec prior to centrifugation at 16,000 x g at 4 oC for 10 min. The supernatants were
then transferred to clean glass tubes and evaporated to dryness under nitrogen. Dried
residues were resuspended in 100 µL of mobile phase A for LC-MS analysis. For
labeling studies cells were grown in media omitting glucose supplemented with 1 mg/mL
[13C6]-glucose. Details of the LC-MS/MS analysis have been describes in detail
previously 108.

Quantification of tamoxifen and metabolites in tumor tissue. Tumor was removed
from mouse under anesthesia and flash frozen in liquid N2. Frozen tissue was weighed
and homogenized by electric homogenizer on ice in 4:1 methanol:water (v/v). Samples
were then centrifuged at 16,000 x g at 4 oC for 10 min. 10 µL of the resulting supernatant
was analyzed by reverse phase LC-MS/MS utilizing teniposide as the internal standard
for absolute quantification.
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siRNA transfection. Cells were grown in 60 mm dishes to approximately 60%
confluency. The cells were transfected with lipofectamine RNAi Max and siRNA to
PRKAA2 at 50 nM mixed in OptiMEM. Transfection mixture was added to the cell culture
plates in complete DMEM and incubated for 24 hrs before the plates were washed and
refed with fresh complete DMEM. Cells were cultured for an additional 48 hrs before
treatment with tamoxifen.

BODIPY 493/503 staining. BODIPY 493/503 was purchased from Molecular Probes.
Staining solution was made up at 2 μg/mL in PBS. After drug treatments, cells were fixed
using 4% paraformaldehyde and stored at 4°C. Neutral lipid staining was performed by
pelleting the cells and re-suspending in staining solution and incubated for 10 mins at
room temperature. Cells were washed 2x with PBS, suspended in 500 µL PBS and
strained. Cells were analyzed for mean BODIPY stain intensity by flow cytometry (FL1H).

[14C] acetate labeling of lipid pools: The protocol has been previously described109.
Briefly, tamoxifen or vehicle treated ells were incubated with [14C]acetate for 2 hours.
The cells were then washed with PBS/EDTA and trypsinized. Pellets were washed twice
with PBS, and fatty acids were extracted with chloroform-methanol (1:1) for 30 min. The
extract was dried under N2 and then extracted with water-saturated butanol. Butanol was
evaporated under N2, and labeled fatty acids were detected by scintillation counting

[35S] labeling. Cells were plated in 60 mm dish and treated for experimental conditions.
Cells were incubated with methionine/cysteine free media for 30 min. Hot labeling media
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was made up at 0.075 mCi/mL [35S]-methionine/cysteine. Cells were incubated with
labeling media for 30 mins. Cells were washed with cold PBS and harvested for protein.
Protein assay performed on cold samples and equal amounts of [35S] labeled protein
were resolved on sodium dodecyl sulfate polyacrylamide gels. Gel was washed with
fixing solution (water with 20% methanol, 10% acetic acid) for 30 min, washed with DI
water, then washed with enlightening solution (PerkinElmer) for 30 min. Gel was dried
overnight using a BioRad gel drying apparatus. The gel was exposed to autoradiography
film at -80°C and film was developed.

Orthotopic xenograft tumors: Four-week old female nu/nu mice were purchased from
Charles River Laboratories and housed in the University of Pennsylvania animal facility
maintained on a 12 h light/dark cycle and given free access to water and food ad libitum.
2x106 4175 cells suspended in 50 µL of a 50/50 mixture of PBS and Matrigel Matrix
basement membrane (Corning) were injected into the mammary fat pad. Tumor growth
was measured twice weekly by calipers. Tumor volume was calculated by the modified
ellipsoid formula: Tumor volume= 1/2(length × width2)110. All animal experiments were
performed in accordance with the “Guide for the Care and Use of Laboratory Animals” of
the National Research Council of the National Academies and approved by the
University of Pennsylvania Institutional Animal Care and Use Committee.

In vivo Tamoxifen and 3BP treatment. Tamoxifen was dissolved 20 mg in 200 µL
ethanol and 800 µL peanut oil. Ethanol was evaporated off overnight. 3BP was dissolved
at 0.5 mg/mL in sterile PBS immediately before injection. Mice were dosed via
intraperitoneal injection.
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Protein analysis from tumors. Tumors were removed under isoflurane anesthesia and
the animals immediately sacrificed. Tumors were flash frozen in liquid N2. Lysis buffer
was 50 mM HEPES pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA. Immediately
before use PMSF, complete mini, and phosphatase inhibitor cocktail was added. On dry
ice, the tumor was cut and random pieces from different sections of the tumor were
weighed and added to lysis buffer at 40mg/mL. The tumor was homogenized by electric
homogenizer on ice. 1% Triton-X was then added and the lysate sonicated. Samples
were then set on ice for 10 minutes then spun at 12000 rpm and 4°C for 10 min and the
pellet discarded.

Statistical analysis: All statistical analyses were performed using a two-tailed Student’s
t test assuming homoscedasticity. A p value < 0.05 was considered statistically
significant.
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